A randomized, double-blind, placebo-controlled, 2-part study of orally administered ALS-008176 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending dosing and multiple ascending dosing in infants hospitalized with respiratory syncytial virus (RSV) infection

Trial Profile

A randomized, double-blind, placebo-controlled, 2-part study of orally administered ALS-008176 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending dosing and multiple ascending dosing in infants hospitalized with respiratory syncytial virus (RSV) infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Lumicitabine (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors Alios BioPharma; Janssen Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2017 Planned End Date changed from 1 Nov 2017 to 30 Mar 2018.
    • 09 Oct 2017 Planned primary completion date changed from 1 Nov 2017 to 30 Mar 2018.
    • 31 May 2017 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top